145 results on '"Scaldaferri, F"'
Search Results
2. OC.07.9: ENDOSCOPIC BALLOON DILATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN'S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE
3. T.11.2: SARCOPENIA AND IBD: MOLECULAR PATHWAYS AND POTENTIAL PHARMACOLOGICAL AND MICROBIAL MODULATORS IN INVITRO MODELS OF INFLAMMATORY BOWEL DISEASE
4. T.05.4: RENAL LITHOGENIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES CORRELATES WITH MICROBIOTA COMPOSITION, URINARY PROFILE AND DIETARY INTAKE
5. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY
6. OC.18.4: MONITORING THE PSYCHOPATHOLOGICAL PROFILE OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH BIOLOGICAL AGENTS
7. OC.07.8: THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
8. T.08.9: SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION
9. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
10. PC.01.2 IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER
11. T.06.3 EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
12. OC.04.3 REAL-LIFE VS TRIAL ACCESS TO BIOLOGIC THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
13. T.06.8 REAL WORD LONG-TERM EFFICACY AND SAFETY OF VEDOLIZUMAB IN MANAGING ULCERATIVE COLITIS VERSUS CROHN'S DISEASE: RESULTS FROM “LONG VEDO” ITALIAN MULTICENTER STUDY
14. OC.08.6 IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMTDERIVED MUCOSAL HEALING
15. OC.12.6 RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
16. OC.17.4 COMBINATION OF ADVANCED THERAPIES IN PATIENTS WITH COMPLEX INFLAMMATORY BOWEL DISEASE
17. OC.10.6 THE ROLE OF OCTN1 IN PREDICTING INDIVIDUAL RESPONSE TO THERAPY IN ULCERATIVE COLITIS: TOWARDS A PERSONALIZED APPROACH
18. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
19. OC.09.1 THE MODERATING EFFECT OF RESILIENCE ON DEPRESSION IN PATIENTS WITH CROHN’S DISEASE
20. OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE
21. OC.04.1 MOLECULAR PATHWAYS OF SARCOPENIA IN DSS ACUTE MODEL OF MURINE COLITIS
22. P.02.12 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY
23. OC.04.5 IL-33/ST2 LEVELS AND GUT MICROBIOTA CHARACTERIZATION CAN PREDICT MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
24. OC.11.4 CHARACTERIZATION OF ESOPHAGEAL MICROBIOTA IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA
25. OC.04.2 ST2+/IL-33 RESPONSIVE CELLS PROMOTE TUMORIGENESIS IN COLITIS-ASSOCIATED COLORECTAL CANCER
26. OC.03.3 THE “DICA” ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS
27. P.07.20 FATIGUE AS A POSSIBLE MARKER OF SARCOPENIA IN INFLAMMATORY BOWEL DISEASE PATIENTS
28. OC.16.1 ALTERATIONS IN CYTOKINE EXPRESSION PROFILE IN COLON MUCOSA OF IBD PATIENTS AND IN RESPONSE TO ANTI-TNF-A TREATMENT
29. P.07.10 OCULAR MANIFESTATIONS IN A TERTIARY IBD CENTER: BETTER TO KEEP AN EYE ON
30. OC.10.2 ANTI-TNF-ALPHA THERAPY INDUCES MICROBIAL AND IMMUNOLOGICAL CHANGES IN DEXTRAN SODIUM SULPHATE CHRONIC COLITIS
31. OC.06.2 LIRAGLUTIDE TREATMENT IN OBESE DIABETIC PATIENTS MODULATES GAS PRODUCTION DURING LACTULOSE BREATH TEST: A NEW POTENTIAL TREATMENT TO MODULATE GUT MICROBIOTA
32. P.10.17 PREVALENCE OF MALNUTRITION IN IBD PATIENTS
33. P.05.7 EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: A PRELIMINARY ANALYSIS FROM THE INTERNATIONAL “DICA” PROSPECTIVE STUDY
34. OC.02.1 IL-33 PROMOTES GUT MUCOSAL WOUND HEALING BY INDUCING MIRNA-320 TO STIMULATE EPITHELIAL RESTITUTION AND REPAIR
35. OC.16.6 EMERGING ROLE OF IL-33/ST2 LEVELS IN PREDICTING MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
36. OC.12.1 THE IMPACT OF TROPHIC EFFECTS OF MULTI STRAIN PROBIOTIC PREPARATION ON PARACELLULAR PERMEABILITY
37. Intestinal permeability is increased in children with irritable bowel syndrome: A case–control study
38. OC.14.6: Escherichia Coli Nissle 1917 Modulate GUT Microbiota Composition in Ulcerative Colitis Patients
39. P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis
40. P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?
41. OC.14.2: Critical Role of the IL-33/ST2 Axis in Colitis-Associated Colorectal Cancer
42. P.03.12: Breath Methane Production in Lactulose Breath Test is Affected by Gender, a Post HOC Italian Study
43. P.12.10 SMALL INTESTINAL BACTERIAL OVERGROWTH IS LINKED TO VASCULAR DISEASE VIA VITAMIN K2-DEPENDENT MECHANISMS
44. P.07.8 IL-33/ST2 AXIS MODULATES EPITHELIAL REPAIR AND GUT MUCOSAL WOUND HEALING IN DSS-COLITIC MICE
45. P.09.15 INCREASED ABUNDANCE OF BENEFICIAL BACTERIA IS ASSOCIATED WITH CLINICAL IMPROVEMENT AFTER RIFAXIMIN TREATMENT
46. P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?
47. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease
48. P.01.1 EFFECT OF BACILLUS CLAUSII IN THE N-METHYLNITROSUREA INDUCED MODEL OF COLONRECTAL CANCER
49. P.06.3 PREVALENCE AND ROLE OF ALEXITHYMIA IN IBD PATIENTS
50. OC.13.4 MULTIPARAMETRIC EVALUATION OF CROHN'S DISEASE: INTESTINAL HEALING BEYOND MUCOSAL HEALING
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.